浙江医药
(600216)
| 流通市值：131.77亿 | | | 总市值：133.19亿 |
| 流通股本：9.51亿 | | | 总股本：9.62亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,190,864,565.87 | 8,880,602,021.78 | 6,695,297,924.39 | 4,322,874,759.83 |
| 营业收入 | 2,190,864,565.87 | 8,880,602,021.78 | 6,695,297,924.39 | 4,322,874,759.83 |
| 二、营业总成本 | 1,909,389,936.37 | 7,817,212,979.34 | 5,638,082,321.04 | 3,511,652,540.63 |
| 营业成本 | 1,422,853,523.48 | 5,801,863,711.11 | 4,184,975,452.75 | 2,601,595,840 |
| 税金及附加 | 19,243,413.84 | 93,298,471.45 | 65,753,990.71 | 39,771,426.47 |
| 销售费用 | 203,560,021.36 | 894,249,972.43 | 673,694,784.67 | 451,716,144.12 |
| 管理费用 | 132,590,853.04 | 520,888,009.22 | 333,640,913.23 | 209,433,285.89 |
| 研发费用 | 93,812,020.95 | 579,884,528.65 | 473,281,101.15 | 313,508,800.49 |
| 财务费用 | 37,330,103.7 | -72,971,713.52 | -93,263,921.47 | -104,372,956.34 |
| 其中:利息费用 | 4,822,645.88 | 24,870,165.4 | 18,476,829.67 | 12,032,068.08 |
| 其中:利息收入 | 9,247,264.04 | 30,144,729.32 | 21,172,025.23 | 15,254,985.23 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -653,522.77 | 4,642,415.19 | 21,364,508.75 | 1,276,670.78 |
| 加:投资收益 | 11,200,069.69 | 2,579,951.77 | 5,364,932.36 | -3,372,533.17 |
| 资产处置收益 | 1,418,473.15 | -81,154.73 | -7,551.84 | 178,709.95 |
| 资产减值损失(新) | 1,444,792.29 | -202,120,062.39 | -94,216,487.48 | -79,707,143.85 |
| 信用减值损失(新) | -3,601,664.06 | 5,797,643.04 | 7,131,143.43 | 5,305,840.36 |
| 其他收益 | 15,071,205.73 | 88,722,257.91 | 51,442,194.83 | 27,095,821.76 |
| 四、营业利润 | 306,353,983.53 | 962,930,093.23 | 1,048,294,343.4 | 761,999,585.03 |
| 加:营业外收入 | 236,054.87 | 4,455,891.04 | 3,963,418.9 | 653,595.98 |
| 减:营业外支出 | 138,552.97 | 15,656,496.03 | 5,951,175 | 3,771,760.85 |
| 五、利润总额 | 306,451,485.43 | 951,729,488.24 | 1,046,306,587.3 | 758,881,420.16 |
| 减:所得税费用 | 48,089,942.49 | 191,490,293.24 | 179,574,974.36 | 134,310,263.92 |
| 六、净利润 | 258,361,542.94 | 760,239,195 | 866,731,612.94 | 624,571,156.24 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 258,361,542.94 | 760,239,195 | 866,731,612.94 | 624,571,156.24 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 287,012,403.51 | 873,380,229.2 | 933,147,906.73 | 673,306,732.88 |
| 少数股东损益 | -28,650,860.57 | -113,141,034.2 | -66,416,293.79 | -48,735,576.64 |
| 扣除非经常损益后的净利润 | 273,967,327.09 | 834,110,178.67 | 890,908,849.74 | 665,480,908.03 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.3 | 0.91 | 0.97 | 0.7 |
| (二)稀释每股收益 | 0.3 | 0.91 | 0.97 | 0.7 |
| 八、其他综合收益 | -8,374,276.06 | 17,625,973.28 | 23,198,143.35 | 28,286,096.28 |
| 归属于母公司股东的其他综合收益 | -7,966,428.67 | 16,631,610.47 | 21,758,147.23 | 26,563,637.2 |
| 九、综合收益总额 | 249,987,266.88 | 777,865,168.28 | 889,929,756.29 | 652,857,252.52 |
| 归属于母公司股东的综合收益总额 | 279,045,974.84 | 890,011,839.67 | 954,906,053.96 | 699,870,370.08 |
| 归属于少数股东的综合收益总额 | -29,058,707.96 | -112,146,671.39 | -64,976,297.67 | -47,013,117.56 |
| 公告日期 | 2026-04-24 | 2026-04-11 | 2025-10-28 | 2025-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |